Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEKT cell therapy in advanced NSCLC
NCT03193567Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2017
- Primary completion
- May 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HEKT cell therapy in non-small cell lung cancer (NSCLC), sponsored by Ruijin Hospital. Primary endpoint: Safety index of blood, heart, lung, kidney and brain function at 2 years. Started Sep 2017; status: recruiting.
02
Drugs
HEKT cell therapy
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03193567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193567.